Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth to ...

"Our revenue volatility is largely in the past as COVID-related uncertainties have diminished," Pfizer's finance chief David ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Pfizer Inc. will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February ...

Although COVID ... vaccine. "We know other countries didn't think Australia had a problem, so we probably weren't a priority," she said. "There was at least one case, I think it was with Pfizer ...